Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis

International Urology and Nephrology

Volumn 46, Issue 1, 2014, Pages 239-242

  Orvain, Corentin ^a,b   Augusto, Jean François ^a,b   Besson, Virginie ^a,b   Marc, Guillaume ^a,b   Coppo, Paul ^c   Subra, Jean François ^a,b   Sayegh, Johnny ^a,b  

^a HIFIH UPRES 3859 SFR 4208 Université LUNAM   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

ADAMTS13; IFN ; Renal failure; Thrombotic microangiopathy

Indexed keywords

ACUTE KIDNEY INJURY; ADAM PROTEINS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN DEFICIENCY; THROMBOSIS;

EID: 84893856365     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0401-7     Document Type: Article

References (12)

1. Zheng XL, Sadler JE (2008) Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol Mech Dis 3:249-277 (Pubitemid 351488282)
2. Zuber J, Martinez F, Droz D et al (2002) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature. Medicine 81(4):321-331 (Pubitemid 34755941)
3. Walther EU, Hohlfeld R (1999) Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 53(8):1622-1627 (Pubitemid 29530329)
4. Broughton A, Cosyns JP, Jadoul M (2011) Thrombotic microangiopathy induced by long-term interferon-B therapy for multiple sclerosis: a case report. Clin Nephrol 76(5):396-400
5. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361(17):1676-1687
6. Sallée M, Crétel E, Jean R et al (2008) Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis. Gastroenterol Clin Biol 32(2):145-146 (Pubitemid 351635692)
7. Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura: Canadian Apherisis Study Group. N Engl J Med 325:393-397
8. Sadler JE (2008) Von Willebrand factor, ADAMTS 13, and thrombotic thrombocytopenic purpura. Blood 102:11-18
9. Ferrari S, Scheiflinger F, Rieger M et al (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109(7):2815-2822 (Pubitemid 46482076)
10. Scully M, Cohen H, Cavenagh J et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136(3):451-461 (Pubitemid 46046304)
11. Froissart A, Buffet M, Veyradier A et al (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French thrombotic microangiopathies reference center. Crit Care Med 40(1):104-111
12. George JN (2012) Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 87:S88-S91